American Society of Hirudotherapy

WP-PEP (LRELEDALEQER)

Thrombin exosite-II-binding 12-residue anticoagulant peptide screened from Whitmania pigra hydrolysates (Hua 2025) via computation-guided strategy.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • WP-PEP (LRELEDALEQER)1.5 kDa
Molecular weight (kilodaltons) of WP-PEP (LRELEDALEQER) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Synthetic analog
Safety domains
Bleeding

Clinical translation limit

WP-PEP's preclinical anticoagulant activity does NOT establish clinical efficacy. No FDA-approved derivative exists; Whitmania pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
1,456 Da
Source species
Whitmania pigra
Discovered
2025 · Hua YT et al.

Biological Targets

  • → thrombin exosite II (Arg233, Arg101 binding residues)

Key Citations

  1. Hua YT et al. (2025), J Pept Sci · PMID 40922112

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.